Patents Assigned to Schering Corporation
  • Publication number: 20120141411
    Abstract: Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.
    Type: Application
    Filed: January 25, 2012
    Publication date: June 7, 2012
    Applicant: Schering Corporation
    Inventors: Stephen D. Hurst, Sandra M. Zurawski, Donna M. Rennick
  • Patent number: 8193319
    Abstract: Engineered antibodies to human IL-17A are provided, as well as uses thereof.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: June 5, 2012
    Assignee: Schering Corporation
    Inventors: Leonard G. Presta, Edward P. Bowman
  • Publication number: 20120134935
    Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Type: Application
    Filed: February 6, 2012
    Publication date: May 31, 2012
    Applicant: Schering Corporation
    Inventors: Joel A. SEQUEIRA, Francis M. CUSS, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani NAGABJUSHAN, James E. PATRICK, Mitchell Cayen
  • Patent number: 8187596
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: May 29, 2012
    Assignee: Schering Corporation
    Inventors: Alissa A. Chackerian, Robert A. Kastelein
  • Publication number: 20120128673
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat S. aureus infection, in particular, S. aureus infections of the lungs. Also provided are use agonists and antagonists of PILR? and PILR?, respectively, to prevent such infections.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 24, 2012
    Applicant: Schering Corporation
    Inventors: Antara Banerjee, Paul G. Heyworth
  • Patent number: 8183252
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: May 22, 2012
    Assignees: Schering Corporation, Pharmacopeia Inc.
    Inventors: Zhaoning Zhu, Zhong-Yue Sun, Andrew Stamford, William J. Greenlee, Jared N. Cumming, Lingyan Wang, Ulrich Iserloh, Xiaoxiang Liu, Ying Huang, Guoqing Li, Jianping Pan
  • Patent number: 8182810
    Abstract: Purified genes encoding cytokine referred to as interleukin-B30 (IL-B30) from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: May 22, 2012
    Assignee: Schering Corporation
    Inventor: J. Fernando Bazan
  • Patent number: 8183287
    Abstract: The present invention provides compositions as well as kits and methods based on a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 that are useful for treating inflammatory disorders.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: May 22, 2012
    Assignee: Schering Corporation
    Inventors: Jim H. Kou, Jonathan D. Eichman
  • Publication number: 20120121601
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 17, 2012
    Applicant: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Publication number: 20120121588
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILR? and PILR? respectively, to prevent the development of sepsis.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 17, 2012
    Applicant: SCHERING CORPORATION
    Inventors: Antara Banerjee, Paul G. Heyworth
  • Patent number: 8178094
    Abstract: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Michael E. Bigler, Drake M. LaFace, Kalyan Pande, Joseph H. Phillips
  • Patent number: 8178095
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
  • Patent number: 8178553
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Shankar B. Bandarpalle, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Aneta Maria Kosinski, Seong-Heon Kim, De-Yi Yang, Razia K. Rizvi
  • Patent number: 8178308
    Abstract: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Rene de Waal Malefyt, Marilyn Travis, Elena Vaisberg
  • Patent number: 8178513
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, U, X, R1, R2, R3, and R4 are as defined herein, and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of using such compounds to inhibit aspartyl protease and to treat a variety of disease or disorders, including cardiovascular diseases, cognitive and neurodegenerative diseases.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: May 15, 2012
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery Inc.
    Inventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voigt, Corey O. Strickland, Elizabeth M. Smith, Andrew W. Stamford, William J. Greenlee, Robert D. Mazzola, Jr., John Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy X. H. Le, Kurt W. Saionz, Suresh D. Babu, Rachael C. Hunter
  • Publication number: 20120115164
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: December 20, 2011
    Publication date: May 10, 2012
    Applicant: Schering Corporation
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Patent number: 8173172
    Abstract: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: May 8, 2012
    Assignee: Schering Corporation
    Inventor: Tsong-Toh Yang
  • Patent number: 8173779
    Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: May 8, 2012
    Assignee: Schering Corporation
    Inventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
  • Patent number: 8173117
    Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Devora L. Rossi, Kevin B Bacon, Bazan Fernando J., Thomas P. Schall, Albert Zlotnik
  • Publication number: 20120107313
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 3, 2012
    Applicant: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham